T
Takashi Shigematsu
Researcher at Wakayama Medical University
Publications - 209
Citations - 5638
Takashi Shigematsu is an academic researcher from Wakayama Medical University. The author has contributed to research in topics: Secondary hyperparathyroidism & Kidney disease. The author has an hindex of 39, co-authored 202 publications receiving 4972 citations. Previous affiliations of Takashi Shigematsu include Chugai Pharmaceutical Co. & Jikei University School of Medicine.
Papers
More filters
Journal ArticleDOI
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
Takashi Shigematsu,Junichiro James Kazama,Takeyoshi Yamashita,Seiji Fukumoto,Tatsuo Hosoya,Fumitake Gejyo,Masafumi Fukagawa +6 more
TL;DR: FGF-23 becomes a potential uremic toxin to decrease 1,25D levels when it loses its hypophosphatemic action because of a decreased number of viable nephrons in patients with advanced renal failure and may be an important determinant in the regulation of mineral metabolism with renal insufficiency.
Journal ArticleDOI
Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder
Masafumi Fukagawa,Keitaro Yokoyama,Fumihiko Koiwa,Masatomo Taniguchi,Tetsuo Shoji,Junichiro James Kazama,Hirotaka Komaba,Ryoichi Ando,Takatoshi Kakuta,Hideki Fujii,Msasaaki Nakayama,Yugo Shibagaki,Seiji Fukumoto,Naohiko Fujii,Motoshi Hattori,Akira Ashida,Kunitoshi Iseki,Takashi Shigematsu,Yusuke Tsukamoto,Yoshiharu Tsubakihara,Tadashi Tomo,Hideki Hirakata,Tadao Akizawa +22 more
TL;DR: CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy, and Tadao Akizawa thank the authors for their help and assistance in the development of this guideline.
Journal ArticleDOI
Overview of Regular Dialysis Treatment in Japan (as of 31 December 2011)
Shigeru Nakai,Yuzo Watanabe,Ikuto Masakane,Atsushi Wada,Tetsuo Shoji,Takeshi Hasegawa,Hidetomo Nakamoto,Kunihiro Yamagata,Junichiro James Kazama,Naohiko Fujii,Noritomo Itami,Toshio Shinoda,Takashi Shigematsu,Seiji Marubayashi,Osamu Morita,Seiji Hashimoto,Kazuyuki Suzuki,Naoki Kimata,Norio Hanafusa,Kenji Wakai,Takayuki Hamano,Satoshi Ogata,Kenji Tsuchida,Masatomo Taniguchi,Hiroshi Nishi,Kunitoshi Iseki,Yoshiharu Tsubakihara +26 more
TL;DR: A nationwide statistical survey of 4255 dialysis facilities was conducted at the end of 2011 and the results included questions related to the Great East Japan Earthquake, which occurred on 11 March 2011.
Journal ArticleDOI
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients
Shohei Nakanishi,Junichiro James Kazama,Tomoko Nii-Kono,Kentaro Omori,Takeyoshi Yamashita,Seiji Fukumoto,Fumitake Gejyo,Takashi Shigematsu,Masafumi Fukagawa +8 more
TL;DR: Serum FGF-23 level was found to be the most useful factor in predicting future development of refractory secondary hyper parathyroidism in long-term dialysis patients with mild secondary hyperparathyroidistan.
Journal ArticleDOI
Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
Junichiro James Kazama,Takashi Shigematsu,Kazuki Yano,Eisuke Tsuda,Masakazu Miura,Yoshiko Iwasaki,Yoshindo Kawaguchi,Fumitake Gejyo,Kiyoshi Kurokawa,Masafumi Fukagawa +9 more
TL;DR: It is suggested that OCIF accumulates in serum of patients with renal dysfunction, and may be a candidate uremic toxin responsible for the skeletal resistance to PTH seen in chronic renal failure.